CA2719749A1 - Methods for treating disorders using nmda nr2b-subtype selective antagonist - Google Patents

Methods for treating disorders using nmda nr2b-subtype selective antagonist Download PDF

Info

Publication number
CA2719749A1
CA2719749A1 CA2719749A CA2719749A CA2719749A1 CA 2719749 A1 CA2719749 A1 CA 2719749A1 CA 2719749 A CA2719749 A CA 2719749A CA 2719749 A CA2719749 A CA 2719749A CA 2719749 A1 CA2719749 A1 CA 2719749A1
Authority
CA
Canada
Prior art keywords
pain
disease
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2719749A
Other languages
English (en)
French (fr)
Inventor
John Alan Kemp
Timothy Tasker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec International GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of CA2719749A1 publication Critical patent/CA2719749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2719749A 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist Abandoned CA2719749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4008708P 2008-03-27 2008-03-27
US61/040,087 2008-03-27
PCT/EP2009/002241 WO2009118187A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Publications (1)

Publication Number Publication Date
CA2719749A1 true CA2719749A1 (en) 2009-10-01

Family

ID=40910288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2719749A Abandoned CA2719749A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Country Status (14)

Country Link
US (1) US20110053951A1 (enExample)
EP (1) EP2254580A1 (enExample)
JP (3) JP2011516417A (enExample)
KR (1) KR20100135847A (enExample)
CN (1) CN101977606A (enExample)
AU (1) AU2009228660B2 (enExample)
BR (1) BRPI0909378A2 (enExample)
CA (1) CA2719749A1 (enExample)
IL (1) IL207835A0 (enExample)
MX (1) MX2010009649A (enExample)
NZ (1) NZ588698A (enExample)
RU (1) RU2499598C2 (enExample)
WO (1) WO2009118187A1 (enExample)
ZA (1) ZA201006587B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
WO2015175806A1 (en) 2014-05-16 2015-11-19 The Trustees Of The University Of Pennsylvania Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models
JP6605020B2 (ja) 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｎｒ２ｂ受容体阻害剤としてのトリアゾール
HUE049278T2 (hu) 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Pirazolok
CN107849010B (zh) 2015-06-01 2021-11-09 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物
SMT202000134T1 (it) 2015-07-09 2020-05-08 Janssen Pharmaceutica Nv 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US10732235B2 (en) * 2018-03-29 2020-08-04 Siemens Healthcare Gmbh Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
US11618750B2 (en) 2019-06-14 2023-04-04 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801774T2 (xx) * 1996-03-08 1998-12-21 F.Hoffmann-La Roche Ag 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
DK1070708T3 (da) * 1999-07-21 2004-05-10 Hoffmann La Roche Triazolderivater
EP1278728B1 (en) * 2000-04-20 2004-08-25 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en) * 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1915624A1 (en) * 2005-07-29 2008-04-30 Regents of the University of Minnesota Amyloid beta receptor and uses thereof

Also Published As

Publication number Publication date
JP2011516417A (ja) 2011-05-26
WO2009118187A1 (en) 2009-10-01
MX2010009649A (es) 2010-12-17
ZA201006587B (en) 2012-02-29
AU2009228660A1 (en) 2009-10-01
JP2016094430A (ja) 2016-05-26
NZ588698A (en) 2012-06-29
IL207835A0 (en) 2010-12-30
BRPI0909378A2 (pt) 2015-10-06
AU2009228660B2 (en) 2012-11-29
JP2014098018A (ja) 2014-05-29
RU2499598C2 (ru) 2013-11-27
US20110053951A1 (en) 2011-03-03
EP2254580A1 (en) 2010-12-01
KR20100135847A (ko) 2010-12-27
CN101977606A (zh) 2011-02-16
RU2010143864A (ru) 2012-05-10

Similar Documents

Publication Publication Date Title
CA2719749A1 (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
JP2011516417A5 (enExample)
NZ589445A (en) Rasagiline for parkinson's disease modification
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2004087116A3 (es) Combinación de drogas para la disfunción motora en la enfermedad de parkinson
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
NZ594264A (en) Treatment of dyskinesia related disorders
MX382065B (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmacéuticas, y métodos para su uso.
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
TW200613255A (en) Therapeutic diphenyl ether ligands

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140131

FZDE Discontinued

Effective date: 20170329